ABCG2 and non-small cell lung carcinoma: Increased ABC transporter expression is associated with unfavorable treatment responses leading to reduced survival rates, impacting not only NSCLC but also other tumor types such as glioblastoma, neuroblastoma, and prostate, breast, renal, and thyroid cancers [2].